Table 1. Antibiotic susceptibility pattern of E. coli isolates in percentage which belonged to pathotypic and commensal phylogroups of CA UTI and HA UTI.
E. coli - Escherichia coli, CA - community-acquired, HA - hospital-acquired
Note: p-value shown in the table are calculated by comparing antibiotic-resistant profiles of two groups of E.coli isolates which are associated with CA UTI and HA UTI
| Antimicrobial agent | CA UTI E. coli isolates (N=100) | HA UTI E. coli isolates (N=50) | p-value | ||
| Pathotypic group (B2 and D; N=66), n (%) | Commensal group (A and B1; N=34), n (%) | Pathotypic group (B2 and D; N=24), n (%) | Commensal group (A and B1; N=26), n (%) | ||
| Ampicillin | 50 (75.8) | 28 (82.4) | 24 (100) | 26 (100) | 0.001 |
| Amoxyclav | 49 (74.2) | 26 (76.5) | 23 (95.8) | 26 (100) | 0.001 |
| Norfloxacin | 42 (63.6) | 21 (61.8) | 23 (95.8) | 23 (88.5) | 0.001 |
| Ciprofloxacin | 41 (62.1) | 22 (64.7) | 23 (95.8) | 23 (88.5) | 0.001 |
| Nitrofurantoin | 2 (3) | 0 (0) | 3 (12.5) | 3 (11.5) | 0.017 |
| Co-trimoxazole | 42 (63.6) | 26 (76.5) | 19 (79.2) | 24 (92.3) | 0.001 |
| Gentamicin | 17 (25.8) | 7 (20.6) | 14 (58.3) | 15 (57.7) | 0.001 |
| Amikacin | 15 (22.7) | 2 (5.9) | 13 (54.2) | 14 (53.8) | 0.001 |
| Cefoxitin | 10 (15.1) | 6 (17.7) | 12 (50) | 18 (69.2) | 0.001 |
| Piperacillin/tazobactam | 7 (10.6) | 4 (11.8) | 13 (54.2) | 18 (69.2) | 0.001 |
| Cefazolin | 46 (69.7) | 24 (70.6) | 23 (95.8) | 25 (96.2) | 0.001 |
| Aztreonam | 37 (56) | 19 (55.9) | 20 (83.3) | 17 (65.4) | 0.032 |
| Ceftazidime | 41 (62.1) | 22 (64.7) | 22 (91.6) | 24 (92.3) | 0.001 |
| Cefotaxime | 41 (62.1) | 23 (67.7) | 22 (91.6) | 24 (92.3) | 0.001 |
| Meropenem | 11 (16.7) | 5 (14.7) | 18 (75) | 22 (84.6) | 0.001 |
| Imipenem | 12 (18.1) | 3 (8.8) | 18 (75) | 22 (84.6) | 0.001 |